Selected research
Market Structure
Global Regorafenib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Regorafenib market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Regorafenib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Regorafenib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Regorafenib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Regorafenib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Regorafenib include Beacon Pharmaceuticals, Bayer Pharmaceuticals and Drug International, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Regorafenib market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Regorafenib and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Regorafenib sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Regorafenib market size, projected growth trends, production technologies, key applications, and end-use industries.
Regorafenib Segment by Company
Beacon Pharmaceuticals
Bayer Pharmaceuticals
Drug International
Regorafenib Segment by Type
Bottled Packaging
Film Coated Packaging
Regorafenib Segment by Application
Advanced Hepatocellular Carcinoma
Advanced Gastrointestinal Stromal Tumours
Metastatic Colorectal Cancer
Others
Regorafenib Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Regorafenib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Regorafenib and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Regorafenib.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Regorafenib market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Regorafenib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Regorafenib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Regorafenib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Bottled Packaging
- Film Coated Packaging
Applications
- Advanced Hepatocellular Carcinoma
- Advanced Gastrointestinal Stromal Tumours
- Metastatic Colorectal Cancer
- Others
Companies covered
- Beacon Pharmaceuticals
- Bayer Pharmaceuticals
- Drug International
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Regorafenib Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Regorafenib Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Regorafenib Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Regorafenib Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Regorafenib Market Dynamics
- 2.1 Regorafenib Industry Trends
- 2.2 Regorafenib Industry Drivers
- 2.3 Regorafenib Industry Opportunities and Challenges
- 2.4 Regorafenib Industry Restraints
3 Regorafenib Market by Manufacturers
- 3.1 Global Regorafenib Revenue by Manufacturers (2021-2026)
- 3.2 Global Regorafenib Sales by Manufacturers (2021-2026)
- 3.3 Global Regorafenib Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Regorafenib Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Regorafenib Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Regorafenib Manufacturers, Product Type & Application
- 3.7 Global Regorafenib Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Regorafenib Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Regorafenib Players Market Share by Revenue in 2025
- 3.8.3 2025 Regorafenib Tier 1, Tier 2, and Tier 3
4 Regorafenib Market by Type
- 4.1 Regorafenib Type Introduction
- 4.1.1 Bottled Packaging
- 4.1.2 Film Coated Packaging
- 4.2 Global Regorafenib Sales by Type
- 4.2.1 Global Regorafenib Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Regorafenib Sales by Type (2021-2032)
- 4.2.3 Global Regorafenib Sales Market Share by Type (2021-2032)
- 4.3 Global Regorafenib Revenue by Type
- 4.3.1 Global Regorafenib Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Regorafenib Revenue by Type (2021-2032)
- 4.3.3 Global Regorafenib Revenue Market Share by Type (2021-2032)
5 Regorafenib Market by Application
- 5.1 Regorafenib Application Introduction
- 5.1.1 Advanced Hepatocellular Carcinoma
- 5.1.2 Advanced Gastrointestinal Stromal Tumours
- 5.1.3 Metastatic Colorectal Cancer
- 5.1.4 Others
- 5.2 Global Regorafenib Sales by Application
- 5.2.1 Global Regorafenib Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Regorafenib Sales by Application (2021-2032)
- 5.2.3 Global Regorafenib Sales Market Share by Application (2021-2032)
- 5.3 Global Regorafenib Revenue by Application
- 5.3.1 Global Regorafenib Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Regorafenib Revenue by Application (2021-2032)
- 5.3.3 Global Regorafenib Revenue Market Share by Application (2021-2032)
6 Global Regorafenib Sales by Region
- 6.1 Global Regorafenib Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Regorafenib Sales by Region (2021-2032)
- 6.2.1 Global Regorafenib Sales by Region (2021-2026)
- 6.2.2 Global Regorafenib Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Regorafenib Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Regorafenib Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Regorafenib Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Regorafenib Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Regorafenib Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Regorafenib Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Regorafenib Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Regorafenib Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Regorafenib Revenue by Region
- 7.1 Global Regorafenib Revenue by Region
- 7.1.1 Global Regorafenib Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Regorafenib Revenue by Region (2021-2026)
- 7.1.3 Global Regorafenib Revenue by Region (2027-2032)
- 7.1.4 Global Regorafenib Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Regorafenib Revenue (2021-2032)
- 7.2.2 North America Regorafenib Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Regorafenib Revenue (2021-2032)
- 7.3.2 Europe Regorafenib Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Regorafenib Revenue (2021-2032)
- 7.4.2 Asia-Pacific Regorafenib Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Regorafenib Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Regorafenib Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Beacon Pharmaceuticals
- 8.1.1 Beacon Pharmaceuticals Company Information
- 8.1.2 Beacon Pharmaceuticals Business Overview
- 8.1.3 Beacon Pharmaceuticals Regorafenib Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Beacon Pharmaceuticals Regorafenib Product Portfolio
- 8.1.5 Beacon Pharmaceuticals Recent Developments
- 8.2 Bayer Pharmaceuticals
- 8.2.1 Bayer Pharmaceuticals Company Information
- 8.2.2 Bayer Pharmaceuticals Business Overview
- 8.2.3 Bayer Pharmaceuticals Regorafenib Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Bayer Pharmaceuticals Regorafenib Product Portfolio
- 8.2.5 Bayer Pharmaceuticals Recent Developments
- 8.3 Drug International
- 8.3.1 Drug International Company Information
- 8.3.2 Drug International Business Overview
- 8.3.3 Drug International Regorafenib Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Drug International Regorafenib Product Portfolio
- 8.3.5 Drug International Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Regorafenib Value Chain Analysis
- 9.1.1 Regorafenib Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Regorafenib Production Mode & Process
- 9.2 Regorafenib Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Regorafenib Distributors
- 9.2.3 Regorafenib Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst